Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Payables (2021 - 2025)

Historic Payables for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $627000.0.

  • Lyra Therapeutics' Payables fell 7264.4% to $627000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $627000.0, marking a year-over-year decrease of 7264.4%. This contributed to the annual value of $1.2 million for FY2024, which is 6234.43% down from last year.
  • Lyra Therapeutics' Payables amounted to $627000.0 in Q3 2025, which was down 7264.4% from $680000.0 recorded in Q2 2025.
  • Lyra Therapeutics' Payables' 5-year high stood at $5.1 million during Q3 2023, with a 5-year trough of $627000.0 in Q3 2025.
  • Its 5-year average for Payables is $2.5 million, with a median of $2.6 million in 2022.
  • Its Payables has fluctuated over the past 5 years, first soared by 15077.84% in 2023, then tumbled by 8632.07% in 2025.
  • Lyra Therapeutics' Payables (Quarter) stood at $3.1 million in 2021, then dropped by 16.29% to $2.6 million in 2022, then rose by 19.69% to $3.1 million in 2023, then tumbled by 62.34% to $1.2 million in 2024, then tumbled by 46.82% to $627000.0 in 2025.
  • Its last three reported values are $627000.0 in Q3 2025, $680000.0 for Q2 2025, and $725000.0 during Q1 2025.